OUR INVESTMENTS
We have been proud to participate in financings for the following revolutionary companies:
RNA Editing • CAMBRIDGE, MA
AIRNA Therapeutics is pioneering the discovery and development of RNA editing therapeutics for patients with rare and common diseases.
Preclinical development → IND → Clinical trials → FDA approval
Key co-investor(s): ARCH Venture Partners, Forbion
Small Molecule • CAMBRIDGE, MA
AXONIS Therapeutics is advancing breakthroughs in neuroscience to develop first-in-class precision therapies for neurological disorders.
Preclinical development → IND → Clinical trials → FDA approval
Key co-investor(s): venBio, Sofinnova Investments, MRL Ventures, Perceptive Advisors
Bispecific Antibody • SAN francisco, CA
BioGraph55 is developing bispecific antibodies against a novel subset of immunosuppressive cells to treat resistant cancers.
Preclinical development → IND → Clinical trials → FDA approval
Key co-investor(s): Pfizer Venture Investments, Red Tree Venture Capital
Small molecule • New York, NY
IpiNovyx Bio develops next-generation, ultra-selective proteasome inhibitors for oncology and autoimmune disease applications.
Preclinical development → IND → Clinical trials → FDA approval
Key co-investor(s): Orange Grove Bio, Lilly Ventures
Antibody-RNA Conjugate • Gaithersburg, MD
miRecule is a preclinical-stage biotechnology company developing RNA-based therapeutics for cancer and muscular dystrophy.
Preclinical development → IND → Clinical trials → FDA approval
Key co-investor(s) / Partners: Alexandria Venture Investments / Sanofi
Small molecule • NEW HAVEN, CT
Modifi Bio is a preclinical-stage company creating a new class of oral medicines that selectively kill cancer cells via direct DNA modification.
Key co-investor(s): ACS BrightEdge Fund, HighCape Partners
Acquired by Merck (2024)
sirna • Oxford, UK
Ochre Bio is a computational biology and genetic medicine company developing novel RNA-based therapeutics for chronic liver diseases.
Preclinical development → IND → Clinical trials → FDA approval
Key co-investor(s) / Partners: Khosla Ventures, LifeLink Ventures / Boehringer Ingelheim
Live bacterial therapeutic • Indianapolis, IN
Scioto Biosciences is a clinical-stage biotechnology company developing bacterial therapeutics for GI and neurological diseases.
Preclinical development → IND → Clinical trials → FDA approval
Key co-investor(s): Elevate Ventures
Medtech and other investments
venture fund • London, uk
4BIO is a leading specialist investor in advanced modalities including cell, gene, RNA, and targeted therapies.
bioelectronics • boulder, co
Afference leverages advances in neural engineering to create an artificial sense of touch.
diagnostic • San Francisco, CA
Cytovale interrogates biomechanical properties of immune cells to rapidly diagnose sepsis and other severe immunological diseases.
Medical device • Chicago, IL
Dimension Inx creates advanced biomaterials and biofunctional 3D-printed implants for tissue regeneration and repair.
medical device • Chicago, IL
Simergent is building an automated peritoneal dialysis device that can provide cheaper, safer, and smarter home-based dialysis.